Corrigendum to "The long-acting C5 inhibitor, ravulizumab, is effective and safe in pediatric patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment." Kidney Int. 2021;100:225-237

Collaborators, Affiliations

¹ Paediatric Nephrology Department, University Hospital Vall d'Hebron, Barcelona, Spain. Electronic address: gariceta@vhebron.net.
² Renal Section, Department of Pediatrics, University of Colorado School of Medicine, Aurora, Colorado, USA.
³ Department of Pediatrics, Pusan National University Children's Hospital, Yangsan, Korea.
⁴ Faculty of Pediatric Sciences, Central Michigan University, Mount Pleasant, Michigan, USA.
⁵ Division of Pediatric Nephrology, University of Nebraska Medical Center, Omaha Children's Hospital and Medical Center, Omaha, Nebraska, USA; Department of Nephrology and Hypertension, Division of Pediatrics, University of Utah, Salt Lake City, Utah, USA.
⁶ Clinical and Non-Clinical Pharmacology, Alexion Pharmaceuticals Inc., Boston, Massachusetts, USA.
⁷ Biostatistics, Alexion Pharmaceuticals Inc., Boston, Massachusetts, USA.
⁸ Clinical Development, Alexion Pharmaceuticals Inc., Boston, Massachusetts, USA.
⁹ Division of Pediatric Nephrology, Department of Pediatrics, Seoul National University College of Medicine, Seoul, Korea.
¹⁰ Division of Pediatric Nephrology, Emory University School of Medicine and Children's Healthcare of Atlanta, Atlanta, Georgia, USA.

Free article

Published Erratum

Gema Ariceta et al. Kidney Int. 2023 Jul.

Free article

. 2023 Jul;104(1):205.

doi: 10.1016/j.kint.2023.04.010.

¹ Paediatric Nephrology Department, University Hospital Vall d'Hebron, Barcelona, Spain. Electronic address: gariceta@vhebron.net.
² Renal Section, Department of Pediatrics, University of Colorado School of Medicine, Aurora, Colorado, USA.
³ Department of Pediatrics, Pusan National University Children's Hospital, Yangsan, Korea.
⁴ Faculty of Pediatric Sciences, Central Michigan University, Mount Pleasant, Michigan, USA.
⁵ Division of Pediatric Nephrology, University of Nebraska Medical Center, Omaha Children's Hospital and Medical Center, Omaha, Nebraska, USA; Department of Nephrology and Hypertension, Division of Pediatrics, University of Utah, Salt Lake City, Utah, USA.
⁶ Clinical and Non-Clinical Pharmacology, Alexion Pharmaceuticals Inc., Boston, Massachusetts, USA.
⁷ Biostatistics, Alexion Pharmaceuticals Inc., Boston, Massachusetts, USA.
⁸ Clinical Development, Alexion Pharmaceuticals Inc., Boston, Massachusetts, USA.
⁹ Division of Pediatric Nephrology, Department of Pediatrics, Seoul National University College of Medicine, Seoul, Korea.
¹⁰ Division of Pediatric Nephrology, Emory University School of Medicine and Children's Healthcare of Atlanta, Atlanta, Georgia, USA.

No abstract available

Erratum for

The long-acting C5 inhibitor, ravulizumab, is effective and safe in pediatric patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment.
Ariceta G, Dixon BP, Kim SH, Kapur G, Mauch T, Ortiz S, Vallee M, Denker AE, Kang HG, Greenbaum LA; 312 Study Group. Ariceta G, et al. Kidney Int. 2021 Jul;100(1):225-237. doi: 10.1016/j.kint.2020.10.046. Epub 2020 Dec 8. Kidney Int. 2021. PMID: 33307104 Clinical Trial.